This clinical trial is focused on studying a condition known as fistulizing perianal Crohn’s disease. This is a type of Crohn’s disease that causes abnormal connections, called fistulas, to form near the anus. The trial will evaluate a treatment called Guselkumab, which is a type of medication known as a monoclonal antibody. This medication is designed to help reduce inflammation and improve symptoms in people with this condition. Participants in the study will receive either Guselkumab or a placebo, which is a substance with no active medication.

The purpose of the study is to assess how effective and safe Guselkumab is for treating fistulizing perianal Crohn’s disease. During the study, participants will receive the treatment over a period of time and will be monitored to see how their condition responds. The study will last for several months, and participants will have regular check-ups to track their progress and any changes in their symptoms.

By the end of the study, researchers aim to determine the proportion of participants who achieve combined fistula remission, meaning a significant improvement in their condition, by Week 24. This information will help in understanding the potential benefits of Guselkumab for people with fistulizing perianal Crohn’s disease and may contribute to future treatment options for this challenging condition.